Order Article Reprints

Montella L, Ottaviano M, Riccio V, Picozzi F, Facchini G, Insabato L, Giuliano M, Palmieri G. Results of TETimaX Trial of Langerhans Cell Histiocytosis Treatment and Perspectives on the Role of Imatinib Mesylate in the Era of MAPK Signaling. Biomedicines. 2021; 9(12):1759. https://doi.org/10.3390/biomedicines9121759

Montella, Liliana, Margaret Ottaviano, Vittorio Riccio, Fernanda Picozzi, Gaetano Facchini, Luigi Insabato, Mario Giuliano, and Giovannella Palmieri. 2021. "Results of TETimaX Trial of Langerhans Cell Histiocytosis Treatment and Perspectives on the Role of Imatinib Mesylate in the Era of MAPK Signaling" Biomedicines 9, no. 12: 1759. https://doi.org/10.3390/biomedicines9121759

Montella, L., Ottaviano, M., Riccio, V., Picozzi, F., Facchini, G., Insabato, L., Giuliano, M., & Palmieri, G. (2021). Results of TETimaX Trial of Langerhans Cell Histiocytosis Treatment and Perspectives on the Role of Imatinib Mesylate in the Era of MAPK Signaling. Biomedicines, 9(12), 1759. https://doi.org/10.3390/biomedicines9121759